Abstracts tagged "Mortality"

Abstract Number: 0569 • ACR Convergence 2021
All-Cause and Cause-Specific Mortality in Spondyloarthritis: A Systematic Review and Meta-Analysis
Haseeb Chaudhary¹, Nidrit Bohra², Khezar Syed², Anthony Donato², M.Hassan Murad³ and Paras Karmacharya⁴, ¹Tower Health System, Reading, PA, ²Reading Hospital, Tower Health System, Reading, PA, ³Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN Division of Rheumatology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Spondyloarthritides (SpA) represent a group of chronic inflammatory diseases associated with a higher risk of cardio-metabolic comorbidities compared to the general population. It is…
Abstract Number: 1048 • ACR Convergence 2021
Estimating the Weight of Rheumatologic Diseases in Mortality in Spain: Basic Cause of Death vs Multiple Cause Analysis
ana Perez¹, Fernando Albarran², Cristina Bohorquez², Atusa Movasat², Lucia Ruiz², Paula Pretel², elena Rabadan², Valentina Emperiale², Adrian abbasi³, julio suarez³, lorena montano³, emilio rico³, alfredo prieto⁴, Inmaculada Leon⁵, melchor Alvarez de Mon³ and beatriz perez⁶, ¹Hospital Universitario Príncipe de Asturias. Rheumatology. Medicine Faculty. Alcala University Department., Madrid, Spain, ²Hospital Universitario Príncipe de Asturias, Rheumatology Department, Alcala de Henares, ³Hospital Universitario Príncipe de Asturias, Madrid, Spain, ⁴Faculty of Medicine. Alcala University, Alcala de Henares, Spain, ⁵Communicable Diseases. Instituto de Salud Carlos III, Madrid, Spain, ⁶Department of Epidemiology of Chronic Diseases.National Center of Epidemiology/CIBERESP. Instituto de Salud Carlos III, Madrid, Spain
Background/Purpose: Classical statistics provide information on mortality rates for basic causes of death. Although many inflammatory rheumatic diseases decrease life expectancy, they are generally not…
Abstract Number: 1901 • ACR Convergence 2021
Severe Foot Symptoms Are Associated with Mortality: The Johnston County Osteoarthritis Project
Yvonne Golightly¹, Carolina Alvarez¹, Marian Hannan², Lucy Gates³, Becki Cleveland⁴, Amanda Nelson¹ and Leigh Callahan⁵, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Marcus Institute for Aging Research, Hebrew SeniorLife, Milton, MA, ³University of Southampton, Southampton, United Kingdom, ⁴Thurston Arthritis Research Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ⁵University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC
Background/Purpose: Foot symptoms (i.e., pain, aching, and stiffness [PAS]) are common in middle-aged to older adults and are linked to restricted physical activity, poorer physical…
Abstract Number: 0570 • ACR Convergence 2021
A Narrowed, but Persistent Mortality Gap: A National, Matched Cohort Study in U.S. Veterans with Rheumatoid Arthritis from 2000-2017
Tate Johnson¹, Yangyuna Yang², Punyasha Roul², Brian Sauer³, Joshua Baker⁴, Ted Mikuls² and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Utah, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rheumatoid arthritis (RA) is recognized to increase the risk of premature death. The impact of RA on survival varies across causes of death, though…
Abstract Number: 1060 • ACR Convergence 2021
Temporal Trends of Arthropathies Related Mortality in the United States and Its Regional Variations from 1999-2018
Hafsa Akbar¹, Waqar Mughal², Hasan Mirza³, Ikwinder Kaur⁴, Harjot Jagdey⁵ and Mohsin Mughal⁶, ¹Abington Jefferson Hospital, Abington, PA, ²University of Gujrat, Gujrat, Pakistan, ³Berkshire Medical Center, Pittsfield, MA, ⁴Monmouth Medical Center, an affiliate of Rutgers health system, Long Branch, NJ, ⁵BronxCare Hospital, Bronx, NY, ⁶Monmouth Medical Center, Long Branch, NJ
Background/Purpose: Temporal trends of arthropathies-related mortality in the United States are not well studied. Arthropathies include Infectious arthropathies, Inflammatory poly-arthropathies, osteoarthritis, and other joint disorders.…
Abstract Number: 1909 • ACR Convergence 2021
Impact of Antimalarial Adherence on Cardiovascular Mortality Among Patients with Newly Diagnosed Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-based Study
Md Rashedul Hoque¹, J. Antonio Avina-Zubieta², Diane Lacaille², Mary De Vera³, Yi Qian³, John Esdaile⁴ and Hui Xie⁵, ¹Simon Fraser University, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: Literature has shown poor adherence to antimalarial (AM) medications in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients, with the percentage of adherers…
Abstract Number: 0575 • ACR Convergence 2021
World Mortality of Spondyloarthritis and Inflammatory Bowel Diseases in 2015 and Its Evolution Between 2001 and 2015
Olivier Fakih, Clement Prati, Daniel Wendling and Frank Verhoeven, Service de rhumatologie, CHU de Besançon, Besançon, France
Background/Purpose: There is little epidemiological data on mortality in spondyloarthritis (SpA). This study aimed to determine countries’ mortality rates of ankylosing spondylitis (AS) and psoriatic…
Abstract Number: 1286 • ACR Convergence 2021
Twenty-Year Trends in Systemic Lupus Erythematosus All–Cause Mortality in Mexico: A Nationwide Health Registry
Claudia Mendoza-Pinto¹, Ivet Etchegaray-Morales², Mario García-Carrasco², Pamela Munguía-Realpozo² and Socorro Méndez-Martínez³, ¹Instituto Mexicano del Seguro Social, San Andres Cholula, Mexico, ²Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ³Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: Marked regional variation in systemic lupus erythematosus (SLE) mortality may be due to different spectra of local environmental factors. There have been no large…
Abstract Number: 1918 • ACR Convergence 2021
Don’t Forget About the Arthritis in RA-ILD! Impact of Pulmonary and RA Disease Severity on Survival
Rebecca Brooks¹, Joshua Baker², Yangyuna Yang¹, Punyasha Roul¹, Gail Kerr³, Andreas Reimold⁴, Gary Kunkel⁵, Katherine Wysham⁶, Namrata Singh⁷, Deana Lazaro⁸, Paul Monach⁹, Jill Poole¹, Dana Ascherman¹⁰, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁴University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁵University of Utah, Salt Lake City, UT, ⁶VA Puget Sound/University of Washington, Seattle, WA, ⁷University of Washington, Bellevue, WA, ⁸VA New York Harbor Healthcare system, Brooklyn, NY, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Long-term outcomes following a diagnosis of rheumatoid arthritis associated interstitial lung disease (RA-ILD) are poor, with a median survival estimated between 3 to 8…
Abstract Number: 0592 • ACR Convergence 2021
Gender Modifies the Effect of Rheumatoid Arthritis on All-Cause Mortality
Srikanta Banerjee¹ and Stephanie Falls², ¹Walden University, Leola, ²PA Department of Health, Leola
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease which predominantly affects joints with varying severity. While RA has been found to be…
Abstract Number: 1296 • ACR Convergence 2021
Mortality and Survival in Argentinian Lupus Patients: A Multicenter Study
Maria Constanza Bertolaccini¹, Yessika Soria Curi², Luciana Gonzalez Lucero³, Gabriela Vanesa Espasa², Ana Lucia Barbaglia², Hector Raul Sueldo², Maria Lilia Leguizamon², Susana Marcela Mazza², Mirta Santana², Liliana Maria Galindo², Rodrigo Aguila Maldonado⁴, Mercedes Garcia⁵, Dafne Capelusnik⁶, Ivana Romina Rojas Tessel⁷, Eugenia Picco⁷, Maria Elena Crespo Espindola⁷, Romina Calvo⁸, Susana Roverano⁹, Micaela Ana Cosatti⁹, Cecilia Nora Pisoni⁹, Paola Andrea Avila¹⁰, Marina Micelli¹¹, Maria Hu¹², Lucia Alascio¹³, Maria Cecilia Goizueta¹⁴ and Veronica Ines Bellomio², ¹Hospital Padilla, San Miguel de Tucumán, Argentina, ²Hospital Padilla, Tucuman, Argentina, ³Janssen Cilag Farmaceutica SA, Tucuman, Argentina, ⁴HIGA San Martin La Plata, La Plata, Argentina, ⁵Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ⁶Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Hospital Señor del Milagro, Salta, Argentina, ⁸Hospital José María Cullen, Santa Fe, Argentina, ⁹CEMIC, Buenos Aires, Argentina, ¹⁰Hospital Ramos Mejía, Buenos Aires, Argentina, ¹¹Hospital General de Agudos, Ramos Mejía - CF, Buenos Aires, Argentina, ¹²Hospital José Maria Penna, Buenos Aires, Argentina, ¹³Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ¹⁴Sanatorio 9 de Julio, Tucuman, Argentina
Background/Purpose: The mortality in lupus patients is 2–3 times higher than the general population. However, survival in these patients has improved significantly and it is…
Abstract Number: 0080 • ACR Convergence 2021
One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients
Pedro Gaspar¹, Filipa Farinha², Zara Sayar³, Maria Efthymiou,⁴, Hannah Cohen³ and David Isenberg², ¹Department of Internal Medicine 2, University Hospital of Santa Maria, Lisbon, Portugal, ²Centre for Rheumatology, University College London, London, United Kingdom, ³Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁴Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom
Background/Purpose: The chronic and recurrent nature of antiphospholipid syndrome (APS) leads to damage accrual that impairs long-term functional status and survival. The Damage Index for…
Abstract Number: 0667 • ACR Convergence 2021
Active Screening for Gout Permits Identifying a Larger Cardiovascular Population at High Mortality Risk
Silvia Ruiz-Simón¹, Irene Calabuig², Miguel Gómez-Garberí³ and MARIANO ANDRES⁴, ¹Universidad Miguel Hernández, Alicante, Spain, ²Hospital General Universitario de Alicante, Alicante, Spain, ³Hospital Universitario San Juan de Alicante, San Juan de Alicante, Spain, ⁴Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: We have recently noted by active screening that about a third of gout cases in the cardiovascular population is not registered in records (Calabuig,…
Abstract Number: 1302 • ACR Convergence 2021
Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study
Saira Sheikh¹, Cheng-Chung Wei², Dana Tegzova³, William Stohl⁴, Ricardo Acayaba de Toledo⁵, Tamara Mucenic⁶, Mauricio Abello Banfi⁷, Kathleen Maksimowicz-McKinnon⁸, Carlos Abud-Mendoza⁹, Sandra Navarra¹⁰, Mercedes Garcia¹¹, Ignacio Garcia-De La Torre¹², Regina Kurrasch¹³, Sofia Fernandes¹⁴, Julia Harris¹⁵, Saima Muzaffar¹⁴, Norma Lynn Fox¹³, Andrew Liu¹⁶, Holly Quasny¹⁷ and David Roth¹³, ¹University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²Institute of Medicine, Chung Shan Medical University; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan (Republic of China), ³Institute of Rheumatology, Prague, Czech Republic, ⁴University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil, ⁶Hospital Moinhos de Vento, Porto Alegre, Brazil, ⁷Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, ⁸Henry Ford Hospital, Wayne State University, Detroit, MI, ⁹Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatología y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ¹⁰University of Santo Tomas Hospital, Manila, Philippines, ¹¹Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ¹²Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, ¹³GlaxoSmithKline, Collegeville, PA, ¹⁴GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ¹⁵GlaxoSmithKline, Uxbridge, United Kingdom, ¹⁶GlaxoSmithKline, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Belimumab (BEL) is a recombinant IgG1λ monoclonal antibody that is approved for treatment of systemic lupus erythematosus (SLE). Although clinical studies of BEL have…
Abstract Number: 0083 • ACR Convergence 2021
Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
Tali Eviatar¹, Stanley Niznik², Nancy Agmon-Levin² and Daphna Paran³, ¹Tel Aviv Sourasky Medical Center, Givataim, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel
Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].